Long-term clinical outcome after alcohol septal ablation for obstructive hypertrophic cardiomyopathy: results from the Euro-ASA registry
Language English Country England, Great Britain Media print-electronic
Document type Journal Article, Multicenter Study, Observational Study
PubMed
26746632
DOI
10.1093/eurheartj/ehv693
PII: ehv693
Knihovny.cz E-resources
- Keywords
- Alcohol septal ablation, Prognosis, Survival,
- MeSH
- Ablation Techniques methods mortality MeSH
- Ethanol therapeutic use MeSH
- Cardiomyopathy, Hypertrophic mortality therapy MeSH
- Kaplan-Meier Estimate MeSH
- Middle Aged MeSH
- Humans MeSH
- Disease-Free Survival MeSH
- Risk Factors MeSH
- Solvents therapeutic use MeSH
- Heart Septum MeSH
- Treatment Outcome MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Multicenter Study MeSH
- Observational Study MeSH
- Names of Substances
- Ethanol MeSH
- Solvents MeSH
AIMS: The first cases of alcohol septal ablation (ASA) for obstructive hypertrophic cardiomyopathy (HCM) were published two decades ago. Although the outcomes of single-centre and national ASA registries have been published, the long-term survival and clinical outcome of the procedure are still debated. METHODS AND RESULTS: We report long-term outcomes from the as yet largest multinational ASA registry (the Euro-ASA registry). A total of 1275 (58 ± 14 years, median follow-up 5.7 years) highly symptomatic patients treated with ASA were included. The 30-day post-ASA mortality was 1%. Overall, 171 (13%) patients died during follow-up, corresponding to a post-ASA all-cause mortality rate of 2.42 deaths per 100 patient-years. Survival rates at 1, 5, and 10 years after ASA were 98% (95% CI 96-98%), 89% (95% CI 87-91%), and 77% (95% CI 73-80%), respectively. In multivariable analysis, independent predictors of all-cause mortality were age at ASA (P < 0.01), septum thickness before ASA (P < 0.01), NYHA class before ASA (P = 0.047), and the left ventricular (LV) outflow tract gradient at the last clinical check-up (P = 0.048). Alcohol septal ablation reduced the LV outflow tract gradient from 67 ± 36 to 16 ± 21 mmHg (P < 0.01) and NYHA class from 2.9 ± 0.5 to 1.6 ± 0.7 (P < 0.01). At the last check-up, 89% of patients reported dyspnoea of NYHA class ≤2, which was independently associated with LV outflow tract gradient (P < 0.01). CONCLUSIONS: The Euro-ASA registry demonstrated low peri-procedural and long-term mortality after ASA. This intervention provided durable relief of symptoms and a reduction of LV outflow tract obstruction in selected and highly symptomatic patients with obstructive HCM. As the post-procedural obstruction seems to be associated with both worse functional status and prognosis, optimal therapy should be focused on the elimination of LV outflow tract gradient.
Cardiocentre Podlesí Třinec Czech Republic
Department of Cardiology Gentofte Hospital Copenhagen University Hospital Hellerup Denmark
Department of Cardiology Heart and Diabetes Centre NRW Ruhr University Bochum Bad Oyenhausen Germany
Department of Cardiology Martini Hospital Groningen the Netherlands
Department of Cardiology Oslo University Hospital Oslo Norway
Department of Cardiology St Antonius Hospital Nieuwegein Nieuwegein the Netherlands
Department of Interventional Cardiology and Angiology Institute of Cardiology Warsaw Poland
References provided by Crossref.org